Envista Holdings Corp Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Q3 Results: Posted solid quarter with strong revenue and earnings growth, adjusted EBITDA margin 14.5% (up over 500 basis points from Q3 '24), adjusted EPS $0.32 (more than twice Q3 '24 result).
• Year-to-Date Performance: Core growth ~3% after normalizing for Spark deferral and dealer inventory changes. Year-to-date adjusted EBITDA margin ~13%, adjusted EPS $0.82 (up 67% y-o-y).
• Full Year 2025 Guidance: Raised core revenue growth to approximately 4% (from 3%-4% previously), adjusted EPS to $1.10-$1.15 (from $1.05-$1.15), EBITDA margin unchanged at ~14%.
• Growth Initiatives: Balanced volume and price across portfolio; strong R&D and sales/marketing investment; new product launches (Spark Jr., Spark StageRx, Orascoptic Ergo Zoom, DEXIS Imprevo IOS); trained over 15,000 clinicians through customer education events.
• Operations: Strong contributions from EBS continuous improvement methodology; G&A reductions while maintaining high customer service levels; new R&D/manufacturing facility in China and multipurpose diagnostic center in Finland.
• People: Advancing continuous improvement culture; published 2024 sustainability report highlighting initiatives in access to dental care, colleague/community investment, environmental stewardship.

Segment Performance

• Specialty Products and Technology: Revenue grew 13% year-on-year with core sales up 10.6%. Orthodontics: Spark up high teens before Spark deferral benefit; Brackets & Wires flat due to VBP preparations in China and Q2 buy ahead. Implants had fourth consecutive quarter of positive growth globally, led by North America. Prosthetics/digital solutions and regenerative biomaterials strong. Adjusted operating margin 15.5%, up 850 basis points.
• Equipment and Consumables: Core sales increased 7.3% in Q3. Consumables had double-digit growth; diagnostics had modest growth for second consecutive quarter. Adjusted operating profit margin roughly flat year-over-year, with profit dollars up about 9%.

Guidance

• Raised core revenue growth to approximately 4% from the prior range of 3%-4%.
• Adjusted EPS guidance increased to $1.10-$1.15 from $1.05-$1.15.
• Full year adjusted EBITDA margin guidance unchanged at approximately 14%.

Risks

• Macro uncertainty impacting discretionary procedure segments.
• Tariff landscape remains fluid, which could compress margins; however, the company is tracking to offset full-year tariff costs.
• VBP in China could impact certain segments like Brackets & Wires.

Question and Answer

• Q: Congrats on a really nice quarter. Paul, one for you. It's nice to see Spark turn profitable in the third quarter. And so now that, that business is profitable, how should we think about the trajectory of margins from here? And then separately, can you talk a little bit about the market share of that business? Where are we today? And where do you think that business can go? A: Allen, thanks for the question. Getting Spark profitable is an important milestone. We expect Spark margins to eventually reach fleet average, helped by unit cost progress, setup/design time improvements, portfolio mix changes, and commercial efficiencies with DSOs. Spark has outgrown the global aligner category every year, grew high teens in Q3 before deferral, and has a compelling competitive position with deep geographies and global supply chain.
• Q: If we go to Slide 9 on the volume mix price added 2.4% to EBITDA, based on our math, it looks like price is a good portion of that. Is there any way you can unpack the contributions within volume, mix and price? And then how should we think about what's embedded within that into 4Q? A: Eric Hammes notes price grew by a little over 200 basis points in the quarter, majority of revenue growth was volume-based. Margin accretion from price was slightly better, from volume slightly less. Mix had a minor offset. For 4Q, margins are expected to be in line with the full-year 14% guide, anchoring on the EPS range of $1.10-$1.15.
• Q: Congrats on the quarter. Paul, I appreciate your comments on the stability of the dental market overall. I was wondering if you could just maybe comment a little bit more about China. We've heard from some competitors that there's been an impact from VBP of people pausing buying. The consumer environment obviously remains choppy there. So it'd just be helpful if maybe you could unpack that a little bit more. A: Paul Keel states VBP for orthodontics is well progressed but may slip into 2026. VBP 2.0 for implants is expected but not communicated, with de-stocking followed by restocking impact expected, and VBP 2.0 likely smaller than VBP 1.
• Q: Maybe if we can dig a little bit more into implants, and this has obviously been an improving trajectory, Paul, since you came in. As you think... Where do you feel best about your positioning on implants right now? And as you think about your R&D and sales expansion efforts, where are the biggest opportunities you have to potentially push harder? A: Paul Keel mentions 4 straight quarters of positive growth, above-market growth in North America, good balance across Premium and Challenger, recent new product launches (multiunit abutment, zirconia bridge), but keeping an eye on China's VBP 2.0.
• Q: Eric, I wanted to just focus on the organic growth adjustments in 3Q is my first question here. You're talking about 5% if we adjust for the Spark deferred. And that, I think, is pretty easy math to get to and makes sense. The $10 million pull forward that was mostly in Brackets & Wires last quarter that helped in 2Q, did that $10 million fully reverse mostly in Brackets & Wires this quarter? And would that 5% core growth that you're saying on an adjusted basis this quarter then be closer to maybe 6%, 6.5%, if I adjust for that? Just anything else that I should adjust for to get to kind of a cleaner core number for the quarter? A: Eric Hammes confirms the Spark deferral impact is clear, no price buy ahead remaining in Q3, underlying growth in Q3 was in the 5%-6% range, with the $10 million pull forward reversing mostly in Brackets & Wires in Q3.
• Q: Given the latest quarterly results in SP&T, what are you seeing in terms of the balance around Brackets & Wires and clear aligners? Do you think clear aligners are back to taking share? A: Paul Keel states no material shift between Brackets & Wires and clear aligners; doctors choose based on patient age, compliance, case severity, and Envista provides good solutions for both, with no structural shift.
• Q: I guess somewhat building off your comments from just a second ago. We've seen just around clear aligners, 1 or 2 of your competitors this quarter actually talking about getting better ROI on Clear Aligner marketing spend, both towards practitioners and consumers to drive better clear aligner volume trends. So I guess, in your journey on getting to this positive operating profit, just remind us whether or not you think your current level of marketing spend related to Spark franchise is adequate in that context? And is there any color just on where does annual marketing spend directionally go from here for Spark either on an absolute dollar basis or a percent of revenue basis, if you think about it in that context? A: Paul Keel states current marketing spend for Spark is appropriate, with marginal increases expected as new geographic markets are entered, and Spark is a $300 million business at scale.
• Q: I guess maybe just on diagnostics, can you elaborate on what you're seeing in the recent trends and maybe give us some color on your outlook for growth going forward? A: Paul Keel mentions diagnostics had several years of contraction but saw positive growth for second consecutive quarter in Q3, helped by the Imprevo IOS launch. Diagnostics growth is supported by interest rate decreases impacting site additions and equipment purchases by clinicians/DSOs, with early signs of recovery but too early to call a full change.